Astex Therapeutics, SuperGen deal

SuperGen will acquire fellow cancer company Astex in a cash and stock deal. Astex shareholders will receive $25 million in cash, plus shares that will represent 35% of the combined company's outstanding shares after the deal closes. Additionally, Astex shareholders will receive an additional $30 million, paid in either stock or cash, over 30 months. ...